{"filing":{"accession_number":"0001193125-26-261698","cik":"0001815442","ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"d13635d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526261698/d13635d8k.htm"},"events":[{"id":6196,"run_id":5441,"accession_number":"0001193125-26-261698","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Jeremy Chadwick, Chief Operating Officer, resigned effective June 5, 2026, for personal reasons. The disclosure centers on the departure of a named executive officer from a C-suite position, which is material to investors assessing management continuity and operational leadership. While he remains as an advisor through November 2026, the principal event is his resignation from the COO role.","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5165,"accession_number":"0001193125-26-261698","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Jeremy Chadwick, Chief Operating Officer, resigned effective June 5, 2026, for personal reasons. The disclosure centers on the departure of a named executive officer from a C-suite position, which is material to investors assessing management continuity and operational leadership. While he remains as an advisor through November 2026, the principal event is his resignation from the COO role.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:06:21.993828+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5165,"accession_number":"0001193125-26-261698","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Jeremy Chadwick, Chief Operating Officer, resigned effective June 5, 2026, for personal reasons. The disclosure centers on the departure of a named executive officer from a C-suite position, which is material to investors assessing management continuity and operational leadership. While he remains as an advisor through November 2026, the principal event is his resignation from the COO role.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:06:21.993828+00:00","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-06-08"}]}